Bingham Private Wealth LLC Takes $669,000 Position in Astrazeneca Plc $AZN

Key Points

• Bingham Private Wealth LLC acquired a new position in AstraZeneca, purchasing 7,281 shares in Q4 valued at approximately $669,000, while institutional investors own about 20.35% of the company.
• Wall Street sentiment is mixed but leans positive: eight analysts rate AZN a Buy and one a Sell, giving a consensus rating of 'Moderate Buy' with a consensus target price of $102.67.
• AstraZeneca has a market cap of $316.95 billion and a P/E of 35.21, a 12‑month range of $132.32–$212.71, and recently paid a $1.595 dividend (ex‑dividend Feb 20) with a payout ratio of about 74.8%.

Bingham Private Wealth LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 7,281 shares of the company's stock, valued at approximately $669,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Lester Murray Antman dba SimplyRich lifted its holdings in shares of Astrazeneca by 0.9% in the 4th quarter. Lester Murray Antman dba SimplyRich now owns 18,063 shares of the company's stock valued at $1,660,000 after buying an additional 162 shares during the period. Freestone Capital Holdings LLC lifted its holdings in shares of Astrazeneca by 6.3% in the 4th quarter. Freestone Capital Holdings LLC now owns 2,886 shares of the company's stock valued at $265,000 after buying an additional 172 shares during the period. Cura Wealth Advisors LLC acquired a new position in shares of Astrazeneca in the 4th quarter valued at about $216,000. Oak Ridge Investments LLC lifted its holdings in shares of Astrazeneca by 4.0% in the 4th quarter. Oak Ridge Investments LLC now owns 97,663 shares of the company's stock valued at $8,978,000 after buying an additional 3,765 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of Astrazeneca by 8.1% in the 4th quarter. Assetmark Inc. now owns 335,387 shares of the company's stock valued at $30,832,000 after buying an additional 25,004 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AZN shares. Morgan Stanley reaffirmed an "overweight" rating on shares of Astrazeneca in a report on Wednesday, April 8th. TD Cowen reaffirmed a "buy" rating on shares of Astrazeneca in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Astrazeneca in a report on Friday, February 6th. Wall Street Zen cut Astrazeneca from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Finally, Citigroup started coverage on Astrazeneca in a report on Tuesday, January 27th. They issued a "buy" rating for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Astrazeneca has a consensus rating of "Moderate Buy" and a consensus target price of $102.67.

Astrazeneca Stock Up 1.1%

NYSE AZN opened at $204.37 on Wednesday. The stock has a market capitalization of $316.95 billion, a P/E ratio of 35.21, a price-to-earnings-growth ratio of 1.52 and a beta of 0.35. Astrazeneca Plc has a twelve month low of $132.32 and a twelve month high of $212.71. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51.

Astrazeneca Announces Dividend

The company also recently announced a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were issued a dividend of $1.595 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca's dividend payout ratio is presently 74.83%.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.